• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection.

作者信息

Shah Hitesh H, Uppal Nupur N, Fishbane Steven

机构信息

Donald and Barbara Zucker School of Medicine at Hofstra, Great Neck, NY.

出版信息

Kidney Med. 2020 May 11;2(3):245-247. doi: 10.1016/j.xkme.2020.05.001. eCollection 2020 May-Jun.

DOI:10.1016/j.xkme.2020.05.001
PMID:32734947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7380430/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06dc/7380430/2e15bccad9f7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06dc/7380430/2e15bccad9f7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06dc/7380430/2e15bccad9f7/gr1.jpg

相似文献

1
Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection.炎症与促红细胞生成素低反应性：一种关键联系。
Kidney Med. 2020 May 11;2(3):245-247. doi: 10.1016/j.xkme.2020.05.001. eCollection 2020 May-Jun.
2
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).全球达普司他透析研究（ASCEND-D）中红细胞生成刺激剂低反应性的区域差异。
Am J Nephrol. 2023;54(1-2):1-13. doi: 10.1159/000528696. Epub 2023 Feb 7.
3
Erythropoiesis-stimulating agent hyporesponsiveness.促红细胞生成素刺激剂低反应性
Nephrology (Carlton). 2007 Aug;12(4):321-30. doi: 10.1111/j.1440-1797.2007.00810.x.
4
Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.C反应蛋白水平轻度升高可预测血液透析患者中促红细胞生成素低反应性的发生率。
Nephron. 2015;131(2):123-30. doi: 10.1159/000438870. Epub 2015 Sep 8.
5
Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.终末期肾病患者对促红细胞生成素的低反应性
Contrib Nephrol. 2015;185:76-86. doi: 10.1159/000380972. Epub 2015 May 19.
6
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.探寻红细胞生成刺激剂（ESA）低反应性的潜在预测因子：一项基于人群的研究。
BMC Nephrol. 2019 Sep 14;20(1):359. doi: 10.1186/s12882-019-1554-0.
7
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.当代血液透析患者中红细胞生成刺激剂低反应性的范围和负担。
Am J Kidney Dis. 2016 Nov;68(5):763-771. doi: 10.1053/j.ajkd.2016.05.031. Epub 2016 Aug 12.
8
Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS).血液透析患者的炎症与促红细胞生成素刺激剂反应：透析预后与实践模式研究（DOPPS）中贫血管理的自身配对纵向研究
Kidney Med. 2020 Mar 26;2(3):286-296. doi: 10.1016/j.xkme.2020.01.007. eCollection 2020 May-Jun.
9
Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.欧洲血液透析队列中促红细胞生成素刺激剂反应性的诱发因素：病例交叉研究
Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):414-26. doi: 10.1002/pds.3755. Epub 2015 Feb 17.
10
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.一项关于己酮可可碱治疗 CKD 贫血患者促红细胞生成素刺激剂低反应性的随机、安慰剂对照试验：用己酮可可碱处理促红细胞生成素抵抗（HERO）试验。
Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020. Epub 2014 Aug 10.

引用本文的文献

1
Assessing the Impact of Inflammation on Erythropoietin Resistance in Hemodialysis: The Role of the NLR.评估炎症对血液透析中促红细胞生成素抵抗的影响：中性粒细胞与淋巴细胞比值的作用
J Clin Med. 2025 May 13;14(10):3411. doi: 10.3390/jcm14103411.
2
Clinical Implication of HIF-PH Inhibitor in Patients with Heart Failure, Chronic Kidney Disease, and Renal Anemia.缺氧诱导因子脯氨酰羟化酶抑制剂在心力衰竭、慢性肾脏病及肾性贫血患者中的临床意义
J Clin Med. 2024 Dec 13;13(24):7619. doi: 10.3390/jcm13247619.
3
Multi-head self-attention mechanism enabled individualized hemoglobin prediction and treatment recommendation systems in anemia management for hemodialysis patients.

本文引用的文献

1
Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS).血液透析患者的炎症与促红细胞生成素刺激剂反应：透析预后与实践模式研究（DOPPS）中贫血管理的自身配对纵向研究
Kidney Med. 2020 Mar 26;2(3):286-296. doi: 10.1016/j.xkme.2020.01.007. eCollection 2020 May-Jun.
2
Does inflammation affect outcomes in dialysis patients?炎症是否会影响透析患者的预后？
Semin Dial. 2018 Jul;31(4):388-397. doi: 10.1111/sdi.12686. Epub 2018 Mar 7.
3
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.
多头自注意力机制助力于为血液透析患者的贫血管理建立个性化血红蛋白预测及治疗推荐系统。
Heliyon. 2023 Feb 1;9(2):e12613. doi: 10.1016/j.heliyon.2022.e12613. eCollection 2023 Feb.
4
Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence.多组学鉴定 LRRC15 下降为 COVID-19 严重程度标志物，在恢复期存在持续的促血栓形成信号。
Nat Commun. 2022 Dec 15;13(1):7775. doi: 10.1038/s41467-022-35454-4.
5
Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study.达普司他治疗心力衰竭合并慢性肾脏病患者贫血的随机对照研究。
ESC Heart Fail. 2022 Dec;9(6):4291-4297. doi: 10.1002/ehf2.14109. Epub 2022 Aug 18.
6
Effects of Low-Flux and High-Flux Dialysis Membranes on Erythropoietin Responsiveness in Hemodialysis Patients.低通量和高通量透析膜对血液透析患者促红细胞生成素反应性的影响
Int J Nephrol. 2022 Jun 14;2022:2984193. doi: 10.1155/2022/2984193. eCollection 2022.
7
Single-centre cross-sectional study on the impact of cumulative erythropoietin on bone mineral density in maintenance dialysis patients.单中心横断面研究：促红细胞生成素累积剂量对维持性透析患者骨密度的影响。
BMJ Open. 2022 Apr 12;12(4):e056390. doi: 10.1136/bmjopen-2021-056390.
8
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives.慢性肾脏病患者的促红细胞生成素抵抗：当前观点
Int J Nephrol Renovasc Dis. 2020 Oct 8;13:231-237. doi: 10.2147/IJNRD.S239151. eCollection 2020.
靶向缺氧诱导因子治疗慢性肾脏病患者贫血
Am J Nephrol. 2017;45(3):187-199. doi: 10.1159/000455166. Epub 2017 Jan 25.
4
IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients.IL-6 水平、营养状况与现患血液透析患者的死亡率。
Clin J Am Soc Nephrol. 2011 Sep;6(9):2253-63. doi: 10.2215/CJN.01770211. Epub 2011 Aug 18.
5
Hepcidin and disorders of iron metabolism.亚铁调素与铁代谢紊乱。
Annu Rev Med. 2011;62:347-60. doi: 10.1146/annurev-med-050109-142444.
6
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.肾脏疾病和 2 型糖尿病患者的红细胞生成反应和结局。
N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109.
7
Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients.ESA 低反应性和血红蛋白变异性与血液透析患者死亡率的关联。
Nephrol Dial Transplant. 2010 Nov;25(11):3701-6. doi: 10.1093/ndt/gfq287. Epub 2010 May 26.
8
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.对CHOIR试验中促红细胞生成素α剂量及血红蛋白达标结果的二次分析。
Kidney Int. 2008 Sep;74(6):791-8. doi: 10.1038/ki.2008.295. Epub 2008 Jul 2.
9
Epoetin requirements predict mortality in hemodialysis patients.促红细胞生成素需求量可预测血液透析患者的死亡率。
Am J Kidney Dis. 2004 Nov;44(5):866-76.
10
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.炎症会增加血液透析患者的心血管风险及死亡率。
Kidney Int. 1999 Feb;55(2):648-58. doi: 10.1046/j.1523-1755.1999.00273.x.